about
O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patientsImmune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cellsCancer drug resistance: redox resetting renders a wayPolymeric drug delivery for the treatment of glioblastomaThe prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysisSummary of emerging personalized medicine in neuroendocrine tumors: are we on track?DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancerA nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.Advances in the genetics of glioblastoma: are we reaching critical mass?A two-step nucleotide-flipping mechanism enables kinetic discrimination of DNA lesions by AGTInhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumoursCurrent data and strategy in glioblastoma multiformeBCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patientsQuantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas.Tyrosine phosphatase inhibitor-3 sensitizes melanoma and colon cancer to biotherapeutics and chemotherapeutics.Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repairHumanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity.KS900: A hypoxia-directed, reductively activated methylating antitumor prodrug that selectively ablates O(6)-alkylguanine-DNA alkyltransferase in neoplastic cells.O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.Global and gene-specific DNA methylation pattern discriminates cholecystitis from gallbladder cancer patients in Chile.A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomideCurrent trends in targeted therapies for glioblastoma multiformeDNA binding, nucleotide flipping, and the helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapyA new dimethyl sulfoxide-based method for gene promoter methylation detectionPhase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.Use of high-dose chemotherapy in front-line therapy of childhood malignant glioma.Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysisDegradation of NF-κB, p53 and other regulatory redox-sensitive proteins by thiol-conjugating and -nitrosylating drugs in human tumor cells.New developments in the treatment of malignant gliomas.A female adnexal tumor of probable Wolffian origin showing positive O-6-methylguanine-DNA methyltransferase methylation.Direct detection and quantification of abasic sites for in vivo studies of DNA damage and repair.Experience with irinotecan for the treatment of malignant gliomaDose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites.Promoter methylation of tumor suppressor genes in esophageal squamous cell carcinoma.The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.
P2860
Q24607903-3830BEAA-AF49-4450-A834-9ED4E78BB8CDQ24647546-661DBDF6-9058-46CC-88AD-EAD31390FC83Q26750753-8500B2F3-7A63-4842-A5E1-870FBB9546BAQ27010046-0ED1D53F-C2F4-4A36-8B43-57524FBA9E65Q28074595-7AA46CC5-7D24-4ED1-B108-4A41D6AC6122Q28078610-FC93151F-FEE7-4177-8F90-48000C116B79Q28477059-C3F7EC76-43BC-41AF-AD86-A9311F51956CQ30412393-3B51CED5-6EE0-4CDF-B0C9-5EE3D2DE5670Q30426125-30A7AA1E-9608-4213-AAC3-23A98085E3A2Q30481618-A8B8648C-944C-4585-80EC-548924083135Q33396508-3AC70191-B11D-4E85-BCAF-DB94C79DCDFDQ33527073-EF037991-CE85-40F3-A913-31A3D28823DEQ33528294-8EB9B3B9-4F26-4BA5-9957-3DE39CD3B9CCQ34117487-0EA4C654-1820-41FC-B543-6847914E0A20Q34132959-C63196DB-00EA-4791-A748-8A8DDA87E3CDQ34140221-74C486C6-38D7-4C41-9995-9AA30A0CD324Q34478948-89D99856-F75D-4B08-A2FB-BBDB34F75BD1Q34802264-AFE05E5B-9ED8-4D4C-8DA8-4650007F5251Q34810016-EA58A218-2184-4303-AF8F-18D5ABE2CCC2Q34883553-3A3444B9-9AA5-4797-8156-457005C4757BQ35001754-B0BC6DAA-F5D1-4906-BF01-0DDD42FF8B3FQ35088396-516992FB-0929-4DC7-9426-AA0B03B153DBQ35096197-F8ACB5F7-4139-4D57-971E-6203DF3D93B8Q35781382-A1F49E01-D6C0-4DB8-93F2-B5D9FE96D4D6Q35864226-05FE2187-6835-44E3-BD04-7FD1B5CCCE6BQ36012002-FE1678CE-5EC1-43F8-AD30-449F64865CD4Q36103447-80CD974C-00DD-42E0-B7BB-7BF875925528Q36459144-C721DD23-F8B9-4452-BFFC-AA377FBF63C7Q36499230-2624536C-D2B4-495D-9FA1-22D2213F332FQ36668246-8D88F0F6-596E-4498-93EA-8E595E2FBE12Q36702401-7C707296-F94F-42CB-8AF4-3599928E27A3Q36814016-48955A71-9E4D-416C-953B-6D929EA55A73Q36972696-EDDA43FC-8CB9-4B40-BFC0-BF1E30F8AC69Q37121158-95710A1C-2B57-43E2-B22C-2BD4F2BC98C3Q37188627-72EF08E2-53A7-4DBA-B204-3CBCD7427A6BQ37265907-9D55B697-3C4A-4F59-B616-837B547689D2Q37278379-A8B39F29-5476-42DF-B9EA-ABDCCBC091C7Q37349299-074BB7C1-2F8C-49CF-B303-E90698E4AFECQ37354050-4244AF06-7DE9-4474-B374-AAF54478525FQ37372483-E56CC299-17AE-4966-8E6F-2F1274F12F23
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Targeted modulation of MGMT: clinical implications.
@ast
Targeted modulation of MGMT: clinical implications.
@en
type
label
Targeted modulation of MGMT: clinical implications.
@ast
Targeted modulation of MGMT: clinical implications.
@en
prefLabel
Targeted modulation of MGMT: clinical implications.
@ast
Targeted modulation of MGMT: clinical implications.
@en
P1476
Targeted modulation of MGMT: clinical implications.
@en
P2093
Stanton L Gerson
P304
P356
10.1158/1078-0432.CCR-05-2543
P407
P577
2006-01-01T00:00:00Z